World News: 12:00 GMT Wednesday 17th April 2019. [iTeos Therapeutics SA via Globe Newswire via SPi World News]
“I am tremendously excited to announce that patient dosing in our innovative, adaptive Phase 1/1b trial is now underway with EOS100850, our unique and specific A receptor antagonist. We believe we have a potential best-in-class compound, which was carefully designed with differentiating features to maximize the therapeutic window,”
“The A pathway has emerged as one of the most exciting targets due to the emerging clinical evidence validating the important role adenosine plays in suppressing the immune response to cancer in the tumor microenvironment. EOS100850 addresses the therapeutic challenges found within this tumor microenvironment by achieving a higher degree of receptor inhibition with its PK/PD and non-brain penetrant profile and its ability to maintain potent efficacy despite increased levels of adenosine concentrations. We are optimistic that EOS100850 can restore the immune response and may control cancer for patients in multiple indications.”
For more information on this trial, please visit (Identifier: NCT03873883).
Amber Fennell, Mathew Neal and Sukaina VirjiConsilium Strategic Communications+44 203 709 5700
Sarah McCabe and Carl MauchStern Investor Relations, Inc.+ 1 212 362 1200
Globe Newswire: 12:00 GMT Wednesday 17th April 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.